Despite the key function of PI3K/AKT/mTOR activity in a sub-set of BRAF mutated colorectal cancers, few trials have attempted to target the pathway in these cancers or to systematically exploit therapeutically the sub-set with concomitant BRAF and PIK3CA mutations. Here, AKT1 is linked to cancer.